ACB AURORA CANNABIS INC IFRS
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1683541 · Reporting currency CAD · Fiscal year ends 03/31
Financial factors as of 2022-06-30 (FY2022), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | 2025Q4*2025-03-31 | 2025Q3*2024-12-31 | 2025Q2*2024-09-30 | 2025Q1*2024-06-30 | 2022Q4*2022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| Gross profit | 27.56M | 74.94M | 42.19M | 42.92M | — |
| SG&A expense | 28.55M | 23.69M | 22.27M | 22.75M | — |
| Operating income | -24.03M | 32.55M | -2.60M | -981,000 | — |
| Interest expense | 2.52M | 1.98M | 2.17M | 1.76M | — |
| Pretax income | -13.54M | 27.73M | 370,000 | 5.82M | — |
| Net income | -17.18M | 28.23M | -13.21M | 3.75M | 0 |
| EPS (basic) | — | — | — | 0.10 | — |
| EPS (diluted) | — | — | — | 0.10 | — |
| Balance sheet | |||||
| Cash & equivalents | 137.92M | 132.62M | 107.57M | 138.21M | 437.81M |
| Short-term investments | 554,000 | — | — | — | — |
| Receivables | 42.47M | — | — | — | 46.99M |
| Inventory | 187.93M | 186.72M | 169.38M | 164.12M | 116.10M |
| Current assets | 478.33M | 488.55M | 416.07M | 437.74M | 745.12M |
| PP&E, netmay include right-of-use assets (IFRS) | 268.11M | 270.40M | 276.22M | 283.47M | 233.47M |
| Goodwill | 43.87M | — | — | — | 0 |
| Intangibles | 45.16M | — | — | — | 70.70M |
| Total assets | 852.67M | 862.30M | 807.39M | 837.29M | 1.08B |
| Current liabilities | 110.86M | — | — | — | 130.86M |
| Short-term debt | 2.30M | — | — | — | 0 |
| Long-term debt | 40.19M | — | — | — | 0 |
| Total debt | 42.49M | — | — | — | 0 |
| Total liabilities | 244.07M | — | — | — | 422.00M |
| Shareholders' equity | 567.17M | — | — | — | 661.84M |
| Net debt | -95.43M | — | — | — | -437.81M |
| Cash flow statement | |||||
| Operating cash flow | — | — | — | — | — |
| Investing cash flow | -3.87M | -6.74M | -3.71M | -16,000 | — |
| Financing cash flow | 2.88M | -655,000 | — | — | — |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.